NCT06304415

Brief Summary

The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,800

participants targeted

Target at P75+ for all trials

Timeline
129mo left

Started Apr 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress16%
Apr 2024Dec 2036

First Submitted

Initial submission to the registry

March 5, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 12, 2024

Completed
20 days until next milestone

Study Start

First participant enrolled

April 1, 2024

Completed
11.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2035

Expected
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2036

Last Updated

March 18, 2026

Status Verified

August 1, 2025

Enrollment Period

11.7 years

First QC Date

March 5, 2024

Last Update Submit

March 16, 2026

Conditions

Cardiovascular DiseasesHypercholesterolemiaLipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia

Outcome Measures

Primary Outcomes (1)

  • Distribution and prevalence of elevated Lipoprotein(a)

    Investigate the distribution lipoprotein(a) and prevalence of elevated lipoprotein(a) concentrations in various ethnicities.

    3 years

Secondary Outcomes (2)

  • Correlation of lipoprotein(a) with cardiovascular outcomes

    10 years

  • Genetic variants of lipoprotein(a) and cardiovascular outcomes atherosclerotic events

    10 years

Study Arms (1)

Working General Population

Consenting hospital staff are recruited to this study. Blood test and questionnaires are taken at baseline. Prospective follow-up of cardiovascular events are undertaken.

Eligibility Criteria

Age21 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Working general population

You may qualify if:

  • Any healthcare workers working in healthcare settings (regardless of PHI and/or private setting) aged 21 and above OR family member such as father, mother, siblings, grandparents, spouse and children aged 12 and above of recruited staff with high Lpa ≥120nmol/l
  • Study team members can also be recruited because we are trying to find the prevalence of elevated Lp(a)

You may not qualify if:

  • Inability to provide informed consent.
  • Pregnant women.
  • Prisoner

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Trials & Research Unit

Singapore, Singapore, 529889, Singapore

Location

Related Publications (5)

  • Loh WJ, Watts GF. Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle? Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):94-102. doi: 10.1097/MED.0000000000000789. Epub 2022 Dec 5.

    PMID: 36468313BACKGROUND

  • Loh WJ, Chang X, Aw TC, Phua SK, Low AF, Chan MY, Watts GF, Heng CK. Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis. 2022 May;349:160-165. doi: 10.1016/j.atherosclerosis.2021.11.018. Epub 2021 Nov 26.

    PMID: 34887076BACKGROUND

  • Loh WJ, Chan DC, Mata P, Watts GF. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Front Genet. 2022 Apr 27;13:905941. doi: 10.3389/fgene.2022.905941. eCollection 2022.

    PMID: 35571022BACKGROUND

  • Nestel P, Loh WJ, Ward NC, Watts GF. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4281-e4294. doi: 10.1210/clinem/dgac541.

    PMID: 36108076BACKGROUND

  • Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgozoglu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.

    PMID: 36036785BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Blood are collected to measure lipoprotein(a) concentrations, genetic variants and biomarkers.

MeSH Terms

Conditions

HypercholesterolemiaLipoprotein Types--Lp System Lp(A) HyperlipoproteinemiaCardiovascular Diseases

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Loh Wann Jia

    Singhealth Foundation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Primary Investigator and Consultant Endocrinologist.

Study Record Dates

First Submitted

March 5, 2024

First Posted

March 12, 2024

Study Start

April 1, 2024

Primary Completion (Estimated)

December 1, 2035

Study Completion (Estimated)

December 31, 2036

Last Updated

March 18, 2026

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations

SG(1)